Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Samsung Biologics and Pfizer announce US$411M collaboration for biosimilar manufacturing in Korea

Jun 8, 2023

Samsung Biologics and Pfizer announced that they have entered a new long-term strategic partnership for manufacturing of Pfizer’s biosimilars portfolio.  According to a Samsung Biologics company filing, the contract is worth US$411M.  Using its newest facility, Plant 4, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing of biosimilars covering oncology, inflammation, and immunology.

This news comes only days after Samsung Biologics announced it will accelerate the timeline for construction and operations of its new, fifth manufacturing plant.